News
Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback